Updates are available Correction dated 2016-10-06
Click to view Correction: https://doi.org/10.1038/srep34435
-
Authors
Li, Lili
Li, Chen
Mao, Haitao
Du, Zhenfang
Chan, Wai Yee
Murray, Paul
Luo, Bing
Chan, Anthony TC
Mok, Tony SK
Chan, Francis KL
Ambinder, Richard F
Tao, Qian
- License Information
-
More Information
Article History
Received: 15 January 2016
Accepted: 5 May 2016
First Online: 26 May 2016
Change Date: 6 October 2016
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Competing interests
: TSKM has received honoraria from Boehringer Ingelheim, BioMarin Pharmaceuticals, AstraZeneca, Roche/Genentech, Pfi zer, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Janssen, Clovis Oncology, GlaxoSmithKline, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Vertex Pharmaceuticals, Bristol-Myers Squibb, AVEO & Biodesix, Prime Oncology, and Amgen; advisory board fees from AstraZeneca, Roche/Genentech, Pfi zer, Eli Lilly, Boehringer Ingelheim, Merck Serono, Merck Sharp & Dohme, Janssen, Clovis Oncology, BioMarin, GlaxoSmithKline, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Vertex Pharmaceuticals, AVEO & Biodesix, and Bristol-Myers Squibb; and is a shareholder in Sanomic. ATC received honoraria from consulting or Advisory role at Merck, Taiho Pharmaceutical, Roche, Amgen and received research funding from Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Pfizer.
